SAM
REGN icon

SEB Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

SEB Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Buy
24,531
+2,834
+13% +$1.93M 0.06% 272
2026
Q1 		$16.8M Buy
+21,697
New +$16.6M 0.07% 228

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

SEB Asset Management's REGN Position: Q2 2026 in Review

SEB Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 13% in Q2 2026, buying an estimated $1.93M and bringing the position to 24,531 shares worth $15.3M. The position accounts for 0.06% of the portfolio, ranked #272.

SEB Asset Management first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $16.8M in Q1 2026. 1,256 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • SEB Asset Management held 24,531 shares of Regeneron Pharmaceuticals worth $15.3M as of Q2 2026.
  • SEB Asset Management bought 2,834 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.93M.
  • Regeneron Pharmaceuticals made up 0.06% of SEB Asset Management's portfolio in Q2 2026, its #272 holding.
  • SEB Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • SEB Asset Management's Regeneron Pharmaceuticals position peaked at $16.8M in Q1 2026.
  • 1,256 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.